TipRanks
Microbot Medical Inc (DE:CY9D)
FRANKFURT:CY9D
Germany Market
CY9D
Microbot Medical
RESEARCH TOOLSreports

Microbot Medical (CY9D) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

CY9D Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Microbot
Medical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CY9D Stock 12 Month Forecast

Average Price Target

€5.57
▲(349.00% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Microbot Medical in the last 3 months. The average price target is €5.57 with a high forecast of €10.55 and a low forecast of €2.64. The average price target represents a 349.00% change from the last price of €1.24.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","11":"€11","2.75":"€2.75","5.5":"€5.5","8.25":"€8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.54916304,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.567613826666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.63729076,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.255,1.9699356184615384,2.684871236923077,3.3998068553846155,4.114742473846154,4.8296780923076925,5.544613710769231,6.25954932923077,6.974484947692308,7.689420566153847,8.404356184615384,9.119291803076923,9.834227421538461,{"y":10.54916304,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.255,1.586739525128205,1.9184790502564102,2.250218575384615,2.5819581005128205,2.913697625641025,3.2454371507692303,3.5771766758974355,3.9089162010256406,4.240655726153846,4.572395251282051,4.904134776410256,5.235874301538461,{"y":5.567613826666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.255,1.3613300584615384,1.4676601169230767,1.5739901753846153,1.6803202338461538,1.7866502923076921,1.8929803507692307,1.9993104092307692,2.1056404676923077,2.211970526153846,2.3183005846153844,2.424630643076923,2.5309607015384614,{"y":2.63729076,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.584,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.839,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.096,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.689,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.911,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.714,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.665,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.495,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.255,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€10.55Average Price Target€5.57Lowest Price Target€2.64
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Lucid Capital Analyst forecast on DE:CY9D
Alexander Nowak
Lucid Capital
Lucid Capital
€3.52→€2.64
Buy
112.68%
Upside
Reiterated
09/25/26
Microbot Medical price target lowered to $3 from $4 at Lucid CapitalMicrobot Medical price target lowered to $3 from $4 at Lucid Capital
B. Riley Securities Analyst forecast on DE:CY9D
William Wood
B. Riley Securities
B. Riley Securities
€3.52
Buy
183.58%
Upside
Initiated
09/11/26
Analysts Offer Insights on Healthcare Companies: Microbot Medical (NASDAQ: MBOT) and Replimune Group (NASDAQ: REPL)
H.C. Wainwright Analyst forecast on DE:CY9D
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€10.55
Buy
750.74%
Upside
Reiterated
08/20/26
Microbot Medical: Buy Rating Reiterated as LIBERTY Adoption Accelerates; $12 Price Target Maintained
Roth MKM Analyst forecast on DE:CY9D
Kyle Bauser
Roth MKM
Roth MKM
€4.84
Buy
289.92%
Upside
Reiterated
04/14/26
Roth MKM Keeps Their Buy Rating on Microbot Medical (MBOT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Lucid Capital Analyst forecast on DE:CY9D
Alexander Nowak
Lucid Capital
Lucid Capital
€3.52→€2.64
Buy
112.68%
Upside
Reiterated
09/25/26
Microbot Medical price target lowered to $3 from $4 at Lucid CapitalMicrobot Medical price target lowered to $3 from $4 at Lucid Capital
B. Riley Securities Analyst forecast on DE:CY9D
William Wood
B. Riley Securities
B. Riley Securities
€3.52
Buy
183.58%
Upside
Initiated
09/11/26
Analysts Offer Insights on Healthcare Companies: Microbot Medical (NASDAQ: MBOT) and Replimune Group (NASDAQ: REPL)
H.C. Wainwright Analyst forecast on DE:CY9D
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€10.55
Buy
750.74%
Upside
Reiterated
08/20/26
Microbot Medical: Buy Rating Reiterated as LIBERTY Adoption Accelerates; $12 Price Target Maintained
Roth MKM Analyst forecast on DE:CY9D
Kyle Bauser
Roth MKM
Roth MKM
€4.84
Buy
289.92%
Upside
Reiterated
04/14/26
Roth MKM Keeps Their Buy Rating on Microbot Medical (MBOT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTVTvTv Therapeutics
MDWDMediwound
AXGNAxoGen
SIBNSI-Bone
LGNDLigand Pharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Microbot Medical

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
3/11 ratings generated profit
27%
Average Return
-12.99%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 27.27% of your transactions generating a profit, with an average return of -12.99% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
1/11 ratings generated profit
9%
Average Return
-32.66%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -32.66% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
0/11 ratings generated profit
0%
Average Return
-43.57%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -43.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CY9D Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
3
3
2
3
4
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
2
3
4
In the current month, CY9D has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CY9D average Analyst price target in the past 3 months is 5.57.
Each month's total comprises the sum of three months' worth of ratings.

CY9D Financial Forecast

CY9D Earnings Forecast

The previous quarter’s earnings for CY9D were -€0.27.
The previous quarter’s earnings for CY9D were -€0.27.
No data currently available

CY9D Sales Forecast

The previous quarter’s earnings for CY9D were €0.00.
The previous quarter’s earnings for CY9D were €0.00.

CY9D Stock Forecast FAQ

What is DE:CY9D’s average 12-month price target, according to analysts?
Based on analyst ratings, Microbot Medical Inc’s 12-month average price target is 5.57.
    What is DE:CY9D’s upside potential, based on the analysts’ average price target?
    Microbot Medical Inc has 349.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Microbot Medical Inc a Buy, Sell or Hold?
          Microbot Medical Inc has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Microbot Medical Inc’s share price target?
            The average share price target for Microbot Medical Inc is 5.57. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €10.55 ,and the lowest forecast is €2.64. The average share price target represents 349.00% Increase from the current price of €1.24.
              What do analysts say about Microbot Medical Inc?
              Microbot Medical Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Microbot Medical Inc?
                To buy shares of DE:CY9D, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.